Bio: Kyle Fetter has implemented and overseen the commercialization, billing, and reimbursement processes for over 70 unique molecular diagnostic companies releasing new, high-complexity laboratory testing services to the healthcare market. He currently provides strategic direction and oversees the implementation process for molecular diagnostic companies at various stages of commercialization and third-party payer contracting. Fetter also oversees the development and commercialization of new web-based software products at XIFIN, catered to high-complexity testing laboratories.
In addition to actively working with XIFIN’s large molecular diagnostic billing department, Fetter consults with molecular diagnostic companies on projecting cash flow for noncovered services, implementing successful appeals strategies, and how to effectively manage the relationship between sales and reimbursement for new medical technology. He regularly provides insights into the changing landscape of molecular diagnostic reimbursement via webinars, conferences, and XIFIN’s blog. He came to the healthcare industry with a background in technology funding and commercialization.
Fetter has a Bachelor of Arts degree from the University of Southern California and an Master of Business Administration degree from the University of Utah.